Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study

医学 多发性骨髓瘤 微小残留病 肿瘤科 干细胞 内科学 自体干细胞移植 残余物 临床试验 移植 文本挖掘 梅德林 外科 骨移植 生物信息学
作者
Si-Eun Oh,Sung‐Soo Park,Jung Yeon Lee,Jae‐Ho Yoon,Sung-Eun Lee,Hee‐Je Kim,Seung‐Hwan Shin,Young‐Woo Jeon,Seung‐Ah Yahng,Jin Hwa Jung,Ari Ahn,Myungshin Kim,Chang‐Ki Min
出处
期刊:Blood Research [Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis]
卷期号:60 (1): 54-54
标识
DOI:10.1007/s44313-025-00101-6
摘要

PURPOSE: Tandem autologous stem cell transplantation (tASCT) is a viable option for high-risk multiple myeloma (MM) patients. Minimal residual disease (MRD), a real-time surrogate marker of disease burden, serves as a valuable measure of treatment response. This study evaluated the impact of tASCT on MRD dynamics in MM patients. METHODS: We analyzed data from a multicenter registry of 28 patients who underwent tASCT as frontline treatment between January 2019 and October 2024. Eligibility criteria included undergoing two ASCTs within one year, having MRD positivity before tASCT, and completing follow-up MRD assessment. Patients were stratified into two groups: extensive MRD clearance (≥ 50% reduction, n = 18) and modest MRD clearance (< 50% reduction, n = 10). RESULTS: Across the entire cohort, mean MRD decreased from 0.111% pre-tASCT to 0.056% post-tASCT. Three patients achieved MRD negativity, 20 had reductions without negativity, and five experienced increases. The extensive clearance group showed significant MRD reduction (0.152% to 0.017%) and longer progression-free survival (PFS: 37.7 vs. 16.3 months, p = 0.013) compared with the modest clearance group, in which MRD increased (0.175% to 0.830%). Overall survival did not differ significantly. CONCLUSIONS: tASCT provides clinical benefit for MRD-positive MM patients, particularly those achieving significant MRD reduction. These findings support tASCT as a feasible approach for MRD-positive patients following initial ASCT.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
细心无声发布了新的文献求助10
2秒前
hcx完成签到,获得积分10
2秒前
3秒前
acadedog完成签到,获得积分10
3秒前
deardorff发布了新的文献求助20
4秒前
4秒前
星辰大海的应助被谨慎的秋烟采纳,获得30
5秒前
6秒前
佳loong完成签到,获得积分10
7秒前
LuoYR@SZU完成签到,获得积分10
7秒前
7秒前
费劲来到这的Rua完成签到,获得积分10
7秒前
小未来完成签到,获得积分10
8秒前
8秒前
小林子完成签到 ,获得积分10
9秒前
9秒前
七七完成签到,获得积分10
10秒前
jsdiohfsiodhg完成签到,获得积分10
10秒前
chenmianyuan完成签到 ,获得积分10
11秒前
12秒前
13秒前
tian完成签到,获得积分10
13秒前
cosine发布了新的文献求助10
14秒前
喜悦的绫完成签到 ,获得积分10
14秒前
15秒前
16秒前
科研小虫完成签到,获得积分10
17秒前
Lewis完成签到 ,获得积分10
17秒前
小蘑菇的应助被科研通管家采纳,获得10
18秒前
wanci的应助被科研通管家采纳,获得10
18秒前
CipherSage的应助被科研通管家采纳,获得10
18秒前
Akim的应助被科研通管家采纳,获得30
18秒前
guamo完成签到,获得积分10
18秒前
18秒前
kiluto完成签到,获得积分10
19秒前
19秒前
烟花的应助被科研通管家采纳,获得10
19秒前
CAOHOU的应助被科研通管家采纳,获得10
19秒前
星辰大海的应助被科研通管家采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621